Home
Markets
Charts & Ideas
Algo
News
Store
Brokers
Download
Economic Calendar
Trading Signals
WebTerminal
Type
/
to search: @user, $symbol
Search
Log in
Create an account
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
VSTM
#2622
Verastem, Inc.
5.7
2
+1.42%
Sector:
Base:
Profit Currency:
Daily Range
Year Range
Daily Change
+1.42%
Monthly Change
-11.86%
6 month change
-38.49%
Year Change
+6.32%
Previous Close
5.6
4
Open
5.7
2
Bid
Ask
Low
5.7
2
High
5.7
2
Volume
58
Markets
US Stock Market
Healthcare
VSTM
Open full chart
Financials
Overview
Statement
Statistics
Dividends
Quarterly
Annual
Income statement
Balance sheet
Cash flow
Value
2020
2021
2022
2023
2024
Total assets
154.35 M
108.66 M
95.05 M
149.72 M
101.54 M
Total liabilities
39.08 M
21.1 M
47.66 M
71.19 M
130.43 M
Total equity
115.27 M
87.56 M
47.39 M
57.37 M
28.89 M
Total liabilities & shareholders' equities
154.35 M
108.66 M
95.05 M
149.72 M
101.54 M
Total debt
—
—
—
—
—
Net debt
—
—
—
—
—
Verastem Inc
Verastem, Inc., doing business as Verastem Oncology, is an American pharmaceutical company that develops medicines to treat certain cancers. Headquartered and founded in Boston, Massachusetts, the firm is a member of NASDAQ Biotechnology Index.
News
What Makes Verastem (VSTM) a New Buy Stock
Verastem Stock Rises Nearly 8% on Strong Q4 & 2025 Preliminary Results
B.Riley reiterates Buy rating on Verastem stock, maintains $16 target
Verastem reports $17.5 million in Q4 revenue for cancer treatment
Verastem stock rating initiated at Buy by H.C. Wainwright with $18 target
Immuneering: Strong Buy Despite Decline In Share Price On Atebimetinib Data (NASDAQ:IMRX)
Revolution Medicines stock surges over 20% on potential AbbVie acquisition
What's Going On With Verastem Stock Friday? - Verastem (NASDAQ:VSTM)
Verastem stock steady as Mizuho reiterates Outperform rating
Verastem: Downgrading To Buy Based On RAMP-203 Setback In Targeting KRAS G12C NSCLC (VSTM)
Verastem stock falls after discontinuing KRAS G12C lung cancer trial
Verastem discontinues KRAS G12C lung cancer trial to focus on G12D